The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Anemia, Multiple Myeloma
About this trial
This is an interventional treatment trial for Anemia focused on measuring anemia, cancer, quality of life, chemotherapy, hemoglobin, multiple myeloma, transfusion, epoetin alfa, epoetin, erythropoietin
Eligibility Criteria
Inclusion Criteria: Patients with documented multiple myeloma defined by standard criteria, with at least 6 months having elapsed since beginning chemotherapy having a self-care performance score of 0, 1, 2, or 3 (patients' ability to perform daily activities, a score ranging from 0 [fully active, no disease restriction] to 3 [capable of only limited self-care, confined to bed or chair more than 50% of waking hours]) having a life expectancy of at least 3 months having a baseline hemoglobin <11 g/dL and baseline count of <100,000 microliter for developing red cells with an ability to administer self-injections Exclusion Criteria: Patients having clinically significant disease other than cancer having evidence of uncontrolled hypertension or a history of seizure having untreated iron, folate, or Vitamin B12 deficiency receiving a transfusion within 7 days of study entry, or androgen therapy within 1 month of study entry receiving dialysis at baseline screening